



Genomic Prediction
Clinical Laboratory

The Embryo Health Study

A Longitudinal Analysis of PGT
for Polygenic Disease Risk

The Research Study


Patients electing to incorporate Preimplantation Genetic Testing for Aneuploidy (PGT-A) into their IVF treatment plan are eligible to participate in a new clinical trial named **The Embryo Health Study**. PGT-A provides an intervention to improve the success of IVF. Genomic Prediction Clinical Laboratory (GPCL) offers an enhanced investigational method of PGT-A called LifeView. Unlike commonly used methods, LifeView PGT is capable of detecting abnormal ploidy (69,XXX or 23,X), which can occur in 1:150 blastocysts, and may improve the accuracy of predicting mosaicism by determining when chromosomal segregation errors occur during preimplantation development. The current standard of care when using PGT-A is to select a single euploid embryo for transfer based only on morphological grading. LifeView offers an innovative option for selection by providing health scores for each euploid embryo.

Benefits

By participating, patients will have an opportunity to obtain additional information on their embryos' risk of common medical conditions such as diabetes, cancer, and heart disease. If eligible, patients will be able to decide whether to add embryo health scores to their LifeView PGT-A report. This decision can be made after determining how many euploid embryos are available, and at no additional cost to the patient. The Embryo Health Study will investigate patient perspectives, utilization rates, and clinical outcomes of LifeView PGT.

How It Works

In order to participate, patients will be asked to complete a counseling session with GPCL and sign a consent to enroll in the study. Parental saliva kits will be mailed to the patients' home address and sent back to GPCL using prepaid shipping materials. Parental DNA analysis will be performed to further assess eligibility to obtain embryo health scores, which may include testing for the following medical conditions:



- Type 1 Diabetes
- Type 2 Diabetes
- Coronary Artery Disease
- Heart Attack
- Hypercholesterolemia
- Hypertension
- Breast Cancer
- Testicular Cancer
- Prostate Cancer
- Basal Cell Carcinoma
- Malignant Melanoma
- Schizophrenia

Routine IVF care will be provided by the patients' clinical team and participation **can be withdrawn at any time**. Results are available within 14 days from the time biopsy samples are received, and LifeView PGT-A results will be provided in all cases, independent of eligibility or interest in obtaining embryo health scores.

IRB Approved
September 10, 2020

Protocol #20202729
clinicaltrials.gov ID NCT04528498



Genomic Prediction
Clinical Laboratory

+1 (973) 529-4223
service@gpclaboratory.com
www.gpclaboratory.com

675 US Highway One,
North Brunswick, NJ
08902